Company / Net Debt per Share
MoonLake Immunotherapeutics Net Debt per Share History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$4.04
FY2025
5-year range
-$4.04 / -$2.87
FY2024-FY2025
Trend
-40.8%
vs FY2024
Sector context
#73 of 82
Health Care
What the data says
MoonLake Immunotherapeutics's net debt per share of $-4.04 is lower than 89% of companies in the Health Care sector (FY2025).
Based on SEC 10-K filings.
-4.04 in FY2025.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 82This company -$4.04 Sector average $13.70
▼
-129.5% below sector average
Key checks
Key Insights
- In FY2025, net debt per share decreased 40.8% year-over-year.
- Ranks #73 out of 82 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.04 | -40.8% |
| FY2024 | -$2.87 | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026